From Yahoo Finance: 2025-05-31 08:40:00

As of May 29, 2025, the Company had access to $5.7M in cash at bank, $4.4M in escrow for eRapa Phase 3 program, $11.9M Undrawn CPRIT grant for program, and $0.5M in debt. With 50,506,308,922 ordinary shares outstanding, the Company’s market capitalization was $5.4M. The Phase 3 study of eRapa in FAP is in final stages, with recruitment set to begin soon.

The Company’s eRapa Phase 3 program is well-funded with $11.9M CPRIT grant. It has sufficient working capital to fund operations into Q1 2026. With 50,506,308,922 ordinary shares outstanding, the Company’s market capitalization is $5.4M. The Phase 3 study of eRapa in FAP is in final stages, with recruitment to begin in the US and Europe.

The Phase 3 study of eRapa in FAP is in the final stages, with 168 patients to be enrolled in a double-blind placebo-controlled trial. The study will be conducted at approximately 30 clinical sites in the US and Europe. Recruitment is expected to start in the coming weeks, with LumaBridge and Precision for Medicine leading the US and European components.



Read more at Yahoo Finance: Biodexa Pharmaceuticals sees cash runway into 1Q26